The global platform for access to childhood cancer medicines

Cancer medicine shortages for children around the world

OncoAlert and ecancer round up: SABCS 2021

INTEGRATE study: Treatment pathways, outcomes and resource use in patients with multiple myeloma

Glow study: MRD outcomes after fixed-duration Ibr+Ven versus Clb+O for first-line treatment of CLL in elderly or unfit patients

Tisagenlecleucel shows no EFS improvement on standard of care in 2L for aggressive B-cell NHL

Azacitidine, venetoclax and gilteritinib for FLT3-mutated AML

Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory large B-cell lymphoma

Latest in combination therapy for NDMM patients

Lenalidomide and rituximab as front-line chemo-free therapy for elderly frail patients with diffuse large B-cell lymphoma.

Antibody and T-cell responses to COVID-19 vaccination in myeloproliferative neoplasm patients

Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in pts with relapsed/refractory B-cell malignancies